Guggenheim analyst Vamil Divan maintains $Travere Therapeutic (TVTX.US)$ with a buy rating, and adjusts the target price from $23 to $41.
According to TipRanks data, the analyst has a success rate of 53.7% and a total average return of 6.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Travere Therapeutic (TVTX.US)$'s main analysts recently are as follows:
Following a discussion with a nephrology specialist regarding outcomes from the PARASOL Scientific Workshop, there's a noted enthusiasm for the adoption of proteinuria as the primary endpoint in clinical trials. Should regulatory bodies accept this endpoint, it would have favorable implications for Filspari. With the reintroduction of focal segmental glomerulosclerosis (FSGS) into forecasting models, there's a cautious projection of a 2025 market entry, with the perceived likelihood of success being 45%.
Following a recent meeting with stakeholders involved in focal segmental glomerulosclerosis trials, there is an indication that the FDA is open to considering alternatives to eGFR as an endpoint in FSGS. Additionally, there's potential for proteinuria to be recognized as a surrogate endpoint. It is anticipated that Travere will engage with the FDA and aim to submit an sNDA in the coming years. The final outcomes from the meeting are expected to be shared at a future ASN event and through a scientific publication. This development could also enhance Travere's attractiveness as a potential acquisition target.
Following the closure of the PARASOL workshop, there is increased optimism regarding the approval prospects of Filspari for focal segmental glomerulosclerosis (FSGS), resulting in an enhanced estimate of the treatment's probability of success to 75% from the previous 60%.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
